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PCSK9 inhibitors – from discovery of a single mutation 
to a groundbreaking therapy of lipid disorders in one 
decade
Krzysztof Jaworski1, Piotr Jankowski2, Dariusz A. Kosior3
A b s t r a c t
Hypercholesterolemia is one of the main risk factors for coronary heart dis-
ease and significantly contributes to the high mortality associated with car-
diovascular diseases. Statin therapy represents the gold standard in the re-
duction of low-density lipoprotein cholesterol concentration. Nevertheless, 
many patients still cannot achieve the recommended target levels, due to 
either inadequate effectiveness or intolerance of these drugs. Monoclonal 
antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) 
have emerged as a promising option in lipid-lowering treatment. After con-
firmation of their efficacy and safety in clinical trials, evolocumab and aliro-
cumab received approval from the US Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) for introduction into clinical practice. 
In this review, we present a  history of the development and mechanisms 
of action, as well as the results of the most important studies concerning 
PCSK9 inhibitors.
Key words: hypercholesterolemia, proprotein convertase subtilisin/kexin 
type 9, monoclonal antibodies, lipid targets, statin intolerance.
Introduction
For over half a century, hypercholesterolemia has been considered an 
indisputable risk factor for cardiovascular diseases (CVD), especially cor-
onary heart disease (CHD), which is a major cause of death worldwide 
[1]. Introduction of statins into clinical practice revolutionized lipid con-
trol and significantly contributed to the reduction of mortality [2]. Never-
theless, about 50% of treated patients and even 80% of the population 
at very high risk do not achieve the recommended cholesterol values 
[3–5]. This may be partly explained by the ‘rule of 6’, which means that 
every doubling of statin dose causes only a 6% additional decrease in 
the low-density lipoprotein cholesterol (LDL-C) concentration [6]. More-
over, the target levels of lipids are still controversial. The results of recent 
studies supported the concept “the lower the LDL-C, the better”. The 
IMPROVE-IT trial revealed that combining ezetimibe with simvastatin 
therapy caused a further decrease of LDL-C level (53 vs. 70 mg/dl) and 
significantly reduced cardiovascular event rates (32.7% vs. 34.7%) [7]. On 
the other hand, statin intolerance remains an important problem in rou-
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tine clinical settings. Its incidence was reported to 
be as high as 10% to 20% [8, 9]. According to the 
unified definition recommended by the Interna-
tional Lipid Expert Panel (ILEP), statin intolerance 
is an inability to tolerate at least 2 different statins 
(one at the lowest starting average daily dose and 
the other at any dose) because of their adverse 
effects. These include muscle symptoms, head-
ache, sleep disorders, alopecia, rash, dyspepsia, 
nausea, erectile dysfunction, gynecomastia, and/
or arthritis. The diagnosis is supported by the im-
provement of symptoms and/or biomarker chang-
es following dose reduction or drug withdrawal. In 
each case predisposing conditions, such as hypo-
thyroidism and drug-drug interaction, should be 
excluded [10]. These limitations of standard lip-
id-lowering therapy created the need to seek new, 
more effective, as well as safer drugs.
Genetic background
The level of cholesterol depends on hereditary 
factors and lifestyle. In some cases, lipid disorders 
are caused by single genetic mutations of proteins 
involved in metabolic pathways. Familial hyper-
cholesterolemia (FH) may serve as an example 
determined by mutations in the genes encoding 
low-density lipoprotein receptor (LDLR) or apolipo-
protein B (APOB). The prevalence of heterozygous 
FH is estimated at 1 per every 500 individuals in 
European countries. In Poland, more than 80,000 
people may be affected [11]. The contemporary 
data indicate even higher rates of overall frequen-
cy (1 : 200–1 : 300), suggesting > 30 million people 
with FH worldwide [12]. The vast majority of cas-
es remain underdiagnosed and undertreated. The 
main clinical symptoms of FH include xanthelas-
ma palpebrarum, senile corneal arcus and xantho-
mas in the Achilles tendons as well as tendons of 
hand extensor muscles. In heterozygous FH, total 
cholesterol (TC) concentration is usually between 
290 mg/dl and 500 mg/dl (7.5–12.9 mmol/l), while 
in homozygotes it rises to the range of 600–1000 
mg/dl (15.5–25.8 mmol/l). The affected individu-
als suffer from atherosclerosis, which develops at 
an early age and leads to premature myocardial 
infarctions (MI), strokes, and death [13].
In 2003, Abifadel et al. identified a novel muta-
tion in the proprotein convertase subtilisin/kexin 
type 9 (PCSK9) gene in two French families with 
autosomal dominant hypercholesterolemia [14]. 
A  short time later, other scientists reported FH 
cases inherited in a  similar way and proved the 
relationship between polymorphism in the PCSK9 
gene and the levels of TC as well as LDL-C in the 
general population [15, 16]. They noted that phe-
notype varied in accordance with the type of mu-
tation. Gain-of-function mutations cause hyper-
cholesterolemia and represent the least common 
form of FH, albeit associated with the highest risk 
for CHD [17]. Conversely, when the expression of 
PCSK9 is reduced or its activity is blocked, the 
concentration of LDL-C decreases [18]. In the ARIC 
study, nonsense mutations in the PCSK9 gene re-
sulted in a substantial reduction of the LDL-C level 
as well as the incidence of CHD (by 28% and 88% 
in the black population, and by 15% and 47% in 
the white population) [19]. Zhao et al. described 
a woman of African descent who was a compound 
heterozygote for two inactivating mutations in 
the PCSK9 gene. Despite a very low LDL-C plasma 
concentration (14 mg/dl), she showed no signs 
of health problems [20]. These discoveries shed 
a  new light on cholesterol homeostasis and be-
came an incentive for research aimed at designing 
novel lipid-lowering drugs. 
Role of PCSK9 in metabolism
Proprotein convertase subtilisin/kexin type 9 
belongs to the family of enzymes which activate 
or deactivate other proteins by proteolytic cleav-
age. It consists of 692 amino acids encoded by 
a gene located in chromosome 1p32.3. Following 
synthesis in the nucleus, PCSK9 undergoes intra-
molecular autocatalytic cleavage of its N-terminal 
prosegment in the endoplasmic reticulum. This 
process is required for protein maturation and 
secretion. PCSK9 is mainly expressed in the liver, 
but also in neuronal tissue, kidney mesenchy-
mal cells, and intestinal epithelia [21]. Its pivotal 
role in cholesterol metabolism is modulation of 
LDL clearance by disrupting recycling of LDL re-
ceptors (Figure 1). The PCSK9 molecule binds to 
the epidermal growth factor-like repeat A (EGF-A) 
domain of LDLR, which leads to its internalization 
into hepatocytes and subsequently lysosomal 
degradation [22]. It also acts as an intracellular 
chaperone and impairs the transport of LDLR pre-
mature forms to the cell surface membrane [23]. 
Moreover, PCSK9 promotes hepatic and intestinal 
production of the triglyceride-rich APOB lipopro-
teins [24]. 
PCSK9 in physiological and pathological 
conditions
The concentration of PCSK9 varies depending 
on the fasting state (decreased during prolonged 
fasting), gender (higher in women than in men) 
and time of the day (nadir between 3 pm and 
9 pm, peak at around 4 am) [25, 26]. It declines 
in adolescence (boys aged 9–16 years, and girls 
about the age of 16), as well as in postmenopausal 
women. Pregnancy is associated with an increase 
in PCSK9 levels. Growth hormone and estrogen 
play a key role in these phenomena [27]. Lifestyle 
also affects PCSK9 concentration. A  Mediterra-
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nean-type diet reduces it significantly [28]. A sim-
ilar trend was observed in high-fat-fed mice after 
aerobic treadmill exercise training [27].
Changes in PCSK9 level have also been report-
ed in different diseases. The literature concerning 
the influence of insulin on the expression of the 
PCSK9 molecule is inconsistent [27, 29, 30]. How-
ever, in diabetics its concentration is increased 
due to insulin resistance and obesity [27]. The ex-
pression of PCSK9 correlates positively with TSH 
and inversely with thyroid hormones [27, 31].
Patients with chronic kidney disease on hemo-
dialysis therapy have lower PCSK9 values than 
those on peritoneal dialysis therapy [27]. Never-
theless, no relationship between PCSK9 levels and 
kidney function was found [32].
The role of PCSK9 in cases of liver dysfunc-
tion has been assessed in several animal studies. 
PCSK9 modulates the infectivity of the hepatitis 
C virus by down-regulation of its receptors (LDLR 
and CD81). In rats following partial hepatectomy, 
an increase in PCSK9 mRNA was observed. The 
regenerating liver capacity was impaired in PC-
SK9-knockout mice, but resolved after implemen-
tation of a high-cholesterol diet [27].
PCSK9 also influences the immune defense 
system. Inflammation stimulates its expression 
followed by an increase of LDL-C [33]. Walley et 
al. demonstrated that PCSK9 molecules reduce 
pathogen lipid clearance via the LDLR and proved 
that the inhibition of this mechanism can mitigate 
the inflammatory response, as well as improving 
the septic shock outcome [34, 35].
The PCSK9 level in serum is directly correlated 
not only with LDL-C and TC values but also with 
atheroma burden in coronary arteries [36]. This 
was observed in 400 patients with chest pain, 
independently of LDL-C or other CVD risk factors 
[37]. Some PCSK9 gene haplotypes associate with 
the severity of intracranial atherosclerosis and 
incidence of ischemic stroke [38]. Furthermore, 
PCSK9 concentration predicts cardiovascular 
events [39].
Drugs and PCSK9 level
The influence of different drugs on PCSK9 con-
centration has been reported by many authors. 
Careskey et al. demonstrated that treatment with 
atorvastatin increased circulating PCSK9 levels by 
34% and decreased LDL-C by 42% when compared 
with baseline and placebo [40]. Sahebkar et al. 
confirmed these findings in a large meta-analysis 
[41]. The induction of PCSK9 expression involving 
hepatocyte nuclear factor 1 α (HNF1-α) and ste-
rol response element binding protein 2 (SREBP2) 
may diminish the beneficial effect of statins [42]. 
On the other hand, PCSK9 concentration, both 
at baseline and during treatment, may differen-
tiate individuals who respond versus those who 
are resistant to such therapy [43]. Some authors 
claim that fenofibrate reduces PCSK9 values by re-
pressing its promoter activity and stimulating two 
degrading convertases: PC5/6A and furin [44, 45]. 
However, the majority of published reports pres-
ent the opposite result. Sahebkar et al. performed 
a  meta-analysis of 6 studies including a  total of 
Figure 1. A – Recycling of the LDL receptor. B – Degradation of the LDL receptor after binding with PCSK9 molecule
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218 subjects, where he showed that fibrate ther-
apy was associated with a significant increase in 
PCSK9 concentration [46]. Niacin co-administered 
with statin or fibrate counteracts this phenome-
non and improves the efficacy of such therapy 
[47]. Ezetimibe seems to have a neutral influence 
on PCSK9 level [48]. The aforementioned data sug-
gest that the combination of a PCSK9 inhibitor and 
currently available drugs may result in an additive, 
or even synergistic, lipid-lowering effect [49].
Discovery of PCSK9 inhibitors
The first reports regarding such therapy ap-
peared in 2007, when Graham et al. proposed 
antisense oligonucleotide inhibitors of PCSK9 
(ASO) as an attractive approach to the treatment 
of hypercholesterolemia. These agents reduced TC 
concentration by 53% in mice and caused a 2-fold 
increase in hepatic LDLR protein levels [50]. Lind-
holm et al. observed similar changes in nonhu-
man primates [51]. In 2008 Frank-Kamenetsky 
et al. proved that small interfering RNAs (siRNAs) 
decreased the values of PCSK9, APOB, and LDL-C 
without a  measurable influence on either 
high-density lipoprotein cholesterol (HDL-C) or tri-
glycerides (TG) in rodents, as well as cynomolgus 
monkeys [52]. A year later Duff et al. demonstrat-
ed that antibodies targeting PCSK9 can reverse 
the PCSK9-mediated regulation of cell-surface 
LDLR and identified them as potential drugs in the 
therapy of lipid disorders [53]. Chan confirmed 
these findings with results of 36% reduction in 
the TC concentration in mice and 80% reduction 
of LDL-C levels in cynomolgus monkeys by using 
a neutralizing anti-PCSK9 antibody. Furthermore, 
he suggested its synergistic effect with statins 
[54]. Ni et al. and Liang et al. presented similar 
data with other high-affinity anti-PCSK9 antibod-
ies: 1D05-IgG2 and J16, respectively [55, 56]. As 
a consequence of these reports, several pharma-
ceutical companies, such as Regeneron Pharma-
ceuticals, Amgen, Pfizer, and Merck, engaged in 
long-term research aimed at designing the best 
PCSK9 inhibitor [57].
Antibodies targeting PCSK9
Evolocumab (AMG 145)
Evolocumab is a fully human monoclonal IgG2 
antibody directed against PCSK9. In phase I stud-
ies, it reduced LDL-C levels by up to 64% and up to 
81% after one dose of ≥ 21 mg and with repeated 
doses of ≥ 35 mg once a week, respectively [58].
Several phase II trials, such as MENDEL, RUTH-
ERFORD, LAPLACE-TIMI 57, and GAUSS, have con-
firmed the efficacy and safety of evolocumab 
[59–62]. It reduced dose-dependently the LDL-C 
concentration by 39–66% compared with placebo. 
At the end of the 12 weeks of the LAPLACE-TIMI 
57 study, over 90% of patients at high risk 
achieved the recommended LDL-C values of < 70 
mg/dl with evolocumab at doses of 140 mg every 
2 weeks and ≥ 280 mg every 4 weeks [63]. Apart 
from that, it lowered the level of lipoprotein(a) 
(Lp(a)), which is a  proven important risk factor 
in the development of CVD [64, 65]. Active treat-
ment in the RUTHERFORD study was associated 
with a reduction in the levels of Lp(a)by 23–32% 
and TG by 15–20%, while HDL-C increased by 
7% [60]. In the OSLER-1 study, which was com-
posed of patients who had taken part in the 
4 aforementioned trials, evolocumab lowered the 
LDL-C concentration on average by approximate-
ly 50% beyond the values achieved with optimal 
standard therapy. The effect was stable over the 
course of 52 weeks. Conversely, discontinuation of 
treatment caused a  rapid return to the baseline 
[66]. In another combined analysis of OSLER-1 and 
OSLER-2, including the results of phase III studies, 
with 4465 patients enrolled, evolocumab reduced 
LDL-C by 61% after 12 weeks of treatment. The 
rate of cardiovascular events at 1 year was dimin-
ished by 53% compared with standard therapy 
alone (0.95% in the evolocumab group vs. 2.18% 
in the standard therapy group (HR = 0.47; 95% CI: 
0.28–0.78; p = 0.003)) [67]. 
The PROFICIO Program revealed in a group of 
over 1300 patients that evolocumab significant-
ly reduced the levels of LDL-C, APOB, non-HDL-C, 
TG and Lp(a), as well as increasing HDL-C and 
apolipoprotein A1 (APOA1). Adverse events (AEs) 
occurred in 56.8% and 49.2% of patients in the 
evolocumab and placebo groups respectively, but 
only a minority of them (11.5% and 9.6%) were 
assigned as treatment-related events. The most 
common complaints included nasopharyngitis, 
upper respiratory infection symptoms, head-
ache, diarrhea, myalgia, and back pain. Serious 
AEs (SAEs) occurred in 2.0% of patients receiving 
evolocumab and 1.2% of patients in the control 
group, but none of these cases were considered 
treatment-related. Reactions at the site of injec-
tion affected 4.1% and 3.3% of individuals in the 
evolocumab and placebo groups, while muscle-re-
lated AEs concerned 6% and 3.9% of them, re-
spectively. The rate of aspartate aminotransferase 
(AST) and/or alanine aminotransferase (ALT) ele-
vations exceeding the upper limit of normal (ULN) 
by more than 3 times was similar in both study 
arms. An increase in creatine kinase (CK) activity 
more than 5 times the ULN was reported in 1.4% 
and 0.9% of patients taking evolocumab and pla-
cebo, respectively. All changes were asymptomatic 
and resolved spontaneously [68].
In the TESLA trial, evolocumab caused a signifi-
cant and dose-related reduction of LDL-C concen-
tration in homozygous FH patients with defective 
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LDL-R activity. There was no effect in receptor neg-
ative subjects (< 2% LDL-R activity) [69].
The characteristics of the most important stud-
ies concerning evolocumab are presented in Table I 
[70–78]. In summary, in both the phase II and III 
trials, evolocumab administered at doses of 140 mg 
every 2 weeks or 420 mg once a month significant-
ly reduced LDL-C levels by approximately 50–75% 
compared with placebo and 35–45% compared 
with ezetimibe [78]. The important advantage of 
evolocumab from a practical standpoint is the fact 
that there is no necessity of dose adjustments for 
age (18–79 years), gender, race/ethnicity, body 
weight, or statin therapy [78].
Alirocumab (SAR236553/REGN727)
Alirocumab is a  fully human, monoclonal IgG1 
anti-PCSK9 antibody. In 2012, Stein et al. reported 
the results of the phase I study exploring this agent. 
Co-administered with atorvastatin, alirocumab 
reduced LDL-C concentration by 39%, 54%, and 
61%, when taken in doses of 50, 100, and 150 mg, 
respectively [79]. In another study, it reduced LDL-C 
by 40–72% as well as lowering non-HDL-C, APOB, 
and Lp(a) [80]. All patients who received alirocum-
ab and 52% of those treated with atorvastatin 
(80 mg daily) plus placebo attained LDL-C levels of 
less than 100 mg/dl. More than 90% of patients 
from the alirocumab study arm achieved LDL-C lev-
els of less than 70 mg/dl, compared with 17% in 
the control group [81]. In individuals with gain-of-
function mutations in the PCSK9 gene, alirocumab 
reduced LDL-C by 62.5% from the baseline, and by 
53.7% when compared with placebo. The effect 
was sustained after 8 weeks of treatment [82].
Alirocumab not only affects the concentration 
of plasma lipids, but also improves the athero-
sclerosis burden and plaque morphology by re-
ducing macrophage-rich and necrotic areas, while 
increasing the smooth muscle cell and collagen 
content [83]. The PCSK9 and LDL-C levels reach 
a nadir at about 3–4 days and 15 days respective-
ly, following the single administration of a 75 mg 
dose. The pharmacokinetic and pharmacodynam-
ic profiles are similar regardless of the injection 
site (upper arm, abdomen, thigh) [84]. 
The efficacy of alirocumab has been confirmed 
in several phase II and III studies. Their results are 
presented in Table II [85–89]. The data concerning 
the influence of PCSK9 inhibitors on cardiovascu-
lar disease risk are limited, but some trends are 
worth noting. In post hoc analysis of the ODYSSEY 
LONG TERM trial, alirocumab treatment was asso-
ciated with a significantly lower rate of adjudicat-
ed major adverse cardiovascular events (a  com-
posite of death from CHD, nonfatal MI, ischemic 
stroke, and unstable angina requiring hospitaliza-
tion) (1.7% in the alirocumab group versus 3.3% in 
the placebo group (HR = 0.52; 95% CI: 0.31–0.90; 
p = 0.02)) [87].
Bococizumab (RN316/PF-04950615)
Bococizumab is a humanized IgG2Δa monoclo-
nal antibody that binds to PCSK9 and improves 
the LDL clearance by the same mechanism as evo-
lucumab and alirocumab. The results of a phase II 
study and purposes of ongoing phase III trials are 
presented in Table III [90, 91].
PCSK9 antibodies in meta-analyses
Navarese et al. performed a  meta-analysis of 
24 randomized trials that evaluated the effects 
of anti-PCSK9 antibody administration in 10,159 
adults with hypercholesterolemia [92]. In this het-
erogeneous population, PCSK9 inhibition caused 
a significant reduction in the LDL-C concentration, 
by 59% compared with placebo, and 36% com-
pared with ezetimibe. The Lp(a) level decreased by 
approximately 25%, while HDL-C increased by 6% 
relative to both control groups [92]. Lipinski et al. 
obtained similar results in a meta-analysis of 17 
randomized trials composed of 13,083 patients. 
Anti-PCSK9 antibodies reduced LDL-C by 57% 
compared with placebo (p < 0.001) and 36.1% 
compared with ezetimibe (p < 0.001) [93]. Accord-
ing to Li et al., PCSK9 inhibitors provided a sub-
stantial lowering effect on the levels of LDL-C, TC, 
TG, APOB, and Lp(a) and caused an increase in the 
concentrations of HDL-C and APOA1 [94]. The ef-
ficacy of PCSK9 inhibitors was also confirmed by 
Zhang et al., who analyzed the results of 25 ran-
domized trials encompassing 12,200 patients [95]. 
Evolocumab administered as a 420 mg dose once 
a  month significantly reduced LDL-C by an aver-
age of 78.9 mg/dl (54.6% vs. placebo and 36.3% 
vs. ezetimibe). An equal or even greater change 
was observed following biweekly 140 mg doses 
(60.4% vs. placebo). Moreover, the active treat-
ment increased HDL-C by 7.6% vs. placebo, and 
6.4% vs. ezetimibe. Evolocumab generated a sig-
nificant reduction in TC, TC/HDL-C, non-HDL-C and 
very-low-density lipoprotein cholesterol (VLDL-C), 
by 36.7%, 41.3%, 52.1% and 22.8%, respectively, 
with a monthly 420 mg dose. It also lowered APOB, 
APOB/APOA1 and Lp(a). A significant decrease in 
TG and a rise in APOA1 were found in all dosag-
es of evolocumab except for biweekly 105 mg 
administration. Monthly 420 mg and biweekly 
140 mg treatment increased the APOA1 level by 
5.2–6.3% and lowered the TG by 15.7–17.4% com-
pared with placebo. Alirocumab administered at 
biweekly doses of 50 to 150 mg reduced LDL-C by 
52.6% vs. placebo and 29.9% vs. ezetimibe, as well 
as increasing HDL-C by 8% [95].
The influence of PCSK9 inhibitors on the risk 
of cardiovascular events was indicated by Nava-
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rese et al. [92]. In a  group of patients receiving 
anti-PCSK9 antibodies, the rates of all-cause mor-
tality and MI occurrences were reduced by 55% 
(OR = 0.45; 95% CI: 0.23–0.86; p = 0.01) and 51% 
(OR = 0.49; 95% CI: 0.26–0.93; p = 0.03), respec-
tively, relative to placebo. The difference in the risk 
of cardiovascular death was not significant (OR = 
0.50; 95% CI: 0.23–1.10; p = 0.08) [92]. Lipiński 
et al. reported similar results [93]. Anti-PCSK9 an-
tibodies reduced the incidence of all-cause mor-
tality (OR = 0.43; 95% CI: 0.22–0.82; p = 0.01), 
whereas the change in risk of cardiovascular death 
(OR = 0.50; 95% CI: 0.22–1.13; p = 0.10) and car-
diovascular events (OR = 0.67; 95% CI: 0.43–1.04; 
p = 0.07) did not reach statistical significance [93]. 
Large randomized trials are ongoing in order to as-
sess the influence of evolocumab (FOURIER), aliro-
cumab (ODYSSEY OUTCOMES) and bococizumab 
(SPIRE 1, SPIRE 2) on cardiovascular risk [96].
Safety concerns
In the trials conducted to date, anti-PCSK9 
antibodies were generally safe and well tolerat-
ed. Some animal studies yielded concerns about 
higher risk for HCV infection, diabetes and im-
paired hepatic recovery abilities in PCSK9 defi-
ciency. However, no human report currently sup-
ports these hypotheses. The theoretical induction 
of intestinal tumors by an excessive production 
of bile acid was not confirmed in practice. Due 
to the lack of safety evidence during pregnancy, 
PCSK9 inhibitors are contraindicated in this state 
[97]. Nevertheless, bococizumab did not affect 
the embryo-fetal development in an animal study 
[98]. A  few trials revealed that PCSK9 inhibitors 
may increase the risk of neurocognitive adverse 
events (OR = 2.34; 95% CI: 1.11–4.93; p = 0.02) 
when compared with placebo [93]. These cases 
were rare (1.2% in ODYSSEY LONG TERM, 0.9% in 
OSLER) and not associated with on-treatment 
LDL-C levels (number needed to harm – 269) [99, 
100]. The neurocognitive adverse effects of evo-
locumab are being examined in the ongoing EBB-
INGHAUS trial [96]. The influence of PCSK9 inhib-
itors on the concentration of fat-soluble vitamins 
and steroid hormones remained unresolved until 
the results of the DESCARTES study. It showed 
that among patients treated with evolocumab, 
Table III. Clinical trials concerning bococizumab (PF-4950615, RN-316) – SPIRE Program
Phase II
Study Population Dosage LDL-C reduction 
NCT01592240  
(Ballantyne et al.)
(n = 354,  
bococizumab = 253, 
placebo = 101) [90]
Patients with hypercholesterolemia
(LDL-C ≥ 80 mg/dl) during statin 
therapy
50, 100, or 150 mg every 2 weeks, 
200 or 300 mg every 4 weeks 
(doses were reduced if LDL-C levels 
persistently decreased  
to ≤ 25 mg/dl); 
time of treatment = 24 weeks
27–53%  
(vs. placebo)
Phase III – Ongoing
Study Purpose
SPIRE-SI to assess the lipid-lowering effect of bococizumab in subjects with statin intolerance
SPIRE-HF to assess the efficacy, safety and tolerability of bococizumab in subjects with heterozygous 
FH who receive highly effective statins
SPIRE-LDL to assess the efficacy, safety and tolerability of bococizumab in subjects with 
hypercholesterolemia who receive highly effective statins
SPIRE-LL to access the efficacy, safety and tolerability of bococizumab in subjects with hyperlipidemia 
who receive background statin therapy
SPIRE-HR to assess the efficacy, safety and tolerability of bococizumab in subjects with 
hypercholesterolemia who receive highly effective statins
SPIRE-1 to evaluate bococizumab, compared with placebo, in reducing the occurrence of major 
cardiovascular events, including cardiovascular death, MI, stroke, and unstable angina 
requiring urgent revascularization, in high-risk subjects with hypercholesterolemia despite 
background lipid-lowering therapy (LDL-C ≥ 70 mg/dl and < 100 mg/dl or non-HDL-C ≥ 100 
mg/dl and < 130 mg/dl)
SPIRE-2 to evaluate bococizumab, compared with placebo, in reducing the occurrence of major 
cardiovascular events, including cardiovascular death, MI, stroke, and unstable angina 
requiring urgent revascularization, in high-risk subjects with hypercholesterolemia despite 
background lipid-lowering therapy (LDL-C ≥ 100 mg/dl or non-HDL-C ≥ 130 mg/dl)
FH – familial hypercholesterolemia, MI – myocardial infarction.
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vitamin E levels mirrored the changes in lipid frac-
tions, while no dysfunction was observed in either 
adrenal or gonadal steroid hormone metabolism. 
The major source of cholesterol required for ste-
roidogenesis may come from alternative LDL de-
livery pathways, such as endogenous synthesis 
and transport in HDL particles [101]. Anti-drug 
antibodies were detected in some cases, but their 
induction did not affect patient safety [88]. The 
majority of the treated population accepted the 
subcutaneous way of administration with self-in-
jected pre-filled pen or syringe devices, which is 
very important for compliance [102].
Regarding safety analyses, Zhang et al. found 
no significant difference in the occurrence of AEs 
between anti-PCSK9 antibodies and agents used 
in the control groups (placebo or ezetimibe), ex-
cept that alirocumab was associated with an 
increased rate of injection-site reactions (RR = 
1.48; 95% CI: 1.05–2.09; p = 0.02) compared with 
placebo. Liver dysfunction occurred less often in 
patients treated with evolocumab (RR = 0.43; 
95% CI: 0.20–0.93; p = 0.03) [95]. Prevalence of 
SAEs in subjects included in the meta-analysis 
conducted by Navarese et al. was comparable 
(9% in PCSK9 inhibitors and 8% in control groups, 
respectively (OR = 1.01; 95% CI: 0.87–1.18; p = 
0.88). The authors reported a 30% reduction in the 
odds of increased creatine kinase activity among 
subjects using anti-PCSK9 antibodies, which may 
suggest that they even provide a muscle-sparing 
effect [92]. However, these findings must be con-
firmed in the ongoing large, long-term trials with 
prespecified primary CVD endpoints.
Approval status
Alirocumab and evolocumab have been re-
cently registered by the US Food and Drug Ad-
ministration (FDA) for treatment of patients with 
heterozygous FH or atherosclerotic CVD, who, 
despite the use of diet and statins in maximally 
tolerated doses, require an additional reduction 
of LDL-C levels [103]. The European Medicines 
Agency (EMA) has also approved evolocumab 
and alirocumab as the first PCSK9 inhibitors in 
Europe for treatment of adults and adolescents 
(over 12 years old) with primary hypercholester-
olemia or mixed dyslipidemia, who are treated 
with lipid-lowering drugs but remain unable to 
achieve the recommended LDL-C goals. Moreover, 
they can be used in cases of statin intolerance or 
contraindications for their administration [103]. 
According to the recently published American 
Heart Association Statement for FH Manage-
ment, PCSK9 inhibitors should be considered if 
LDL-C is not at goal level in spite of treatment 
consisting of high-intensity statin therapy and 
ezetimibe [104].
Future
Apart from evolocumab, alirocumab and boco-
cizumab, the following PCSK9 targeted antibod-
ies are under assessment: LGT209, 1D05-IgG2, 
LY3015014. RG-7652 was recently withdrawn from 
research for unknown reasons [105]. Other prom-
ising methods of limiting the PCSK9 production or 
autocatalytic cleavage include mimetic peptides, 
adnectin, small molecule inhibitors, antisense oli-
gonucleotides and small interfering RNA oligonu-
cleotides (siRNA) [106]. The siRNA molecules lead 
to degradation of PCSK9 messenger RNA (mRNA) 
and make the process of its translation impossible. 
Thus, they impair both intracellular and extracel-
lular PCSK9 functions. In a phase I study, ALN-PCS, 
one of the siRNA-based drugs, was well tolerated 
and significantly reduced PCSK9 as well as LDL 
cholesterol levels after a single intravenous dose in 
healthy volunteers [107]. Galabova et al. proposed 
a  novel approach by creating a  peptide-based 
anti-PCSK9 vaccine. It may be an attractive thera-
py, but requires further investigation in clinical tri-
als [108, 109]. In the future, an alternative option 
to PCSK9 inhibitors may be provided by APOB pro-
duction inhibitors (mipomersen), microsomal tri-
glyceride transfer protein inhibitors (lomitapide), 
cholesteryl ester transfer protein (CETP) inhibitors 
(anacetrapib) and dual modulator of AMP-kinase 
and ATP-citrate lyase (ETC-1002) [110–112].
Conclusions
The discovery of anti-PCSK9 antibodies seems 
to be a breakthrough for a wide range of patients 
with FH or statin intolerance or at high cardiovas-
cular risk, who cannot achieve LDL-C target val-
ues with currently available drugs. The main ad-
vantages of evolocumab and alirocumab are their 
efficacy and safety, confirmed by many clinical 
trials. PCSK9 inhibitors have started a new era in 
the pharmacotherapy of lipid disorders, which will 
probably bring a remarkable improvement in CVD 
outcomes.
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